Patrick Soon-Shiong

Patrick Soon-Shiong's AcademicInfluence.com Rankings

Patrick Soon-Shiong

Philosophy

#10957

World Rank

#15042

Historical Rank

#2056

USA Rank

Logic

#7794

World Rank

#9670

Historical Rank

#1220

USA Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Patrick Soon-Shiong Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Patrick Soon-Shiong is a South African-American transplant surgeon, billionaire businessman, bioscientist, and media proprietor. He is the inventor of the drug Abraxane, which became known for its efficacy against lung, breast, and pancreatic cancer. Soon-Shiong is the founder of NantWorks, a network of healthcare, biotech, and artificial intelligence startups; an adjunct professor of surgery and executive director of the Wireless Health Institute at the University of California, Los Angeles; and a visiting professor at Imperial College London and Dartmouth College. Soon-Shiong has published more than 100 scientific papers and has more than 230 issued patents worldwide on advancements spanning numerous fields in technology and medicine.

(See a Problem?)

Patrick Soon-Shiong's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. (2006) (989)
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. (2011) (956)
Protein nanoparticles as drug carriers in clinical medicine. (2008) (675)
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. (2002) (609)
Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation (1994) (606)
Alginate polycation microcapsules. I. Interaction between alginate and polycation. (1996) (416)
Induction of Cytokine Production from Human Monocytes Stimulated with Alginate (1991) (361)
SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. (2009) (338)
Alginate polycation microcapsules. II. Some functional properties. (1996) (276)
Long-term reversal of diabetes by the injection of immunoprotected islets. (1993) (227)
SUCCESSFUL REVERSAL OF SPONTANEOUS DIABETES IN DOGS BY INTRAPERITONEAL MICROENCAPSULATED ISLETS (1992) (196)
Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status (2008) (191)
Molecular heterogeneity in breast cancer: State of the science and implications for patient care. (2017) (156)
Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant (2021) (151)
An immunologic basis for the fibrotic reaction to implanted microcapsules. (1991) (140)
Sustained Reduction of In-Stent Neointimal Growth With the Use of a Novel Systemic Nanoparticle Paclitaxel (2002) (135)
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele (2016) (131)
Pro inflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived exosomes (2018) (117)
Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling (2014) (99)
Characterization of the Proinflammatory Profile of Synovial Fluid-Derived Exosomes of Patients with Osteoarthritis (2017) (74)
Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL–Based Paclitaxel (2006) (71)
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations (2020) (62)
Single-cell sequencing and tumorigenesis: improved understanding of tumor evolution and metastasis (2017) (60)
A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival (2020) (50)
Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition (2018) (50)
Interpenetrating polymer networks of alginate and polyethylene glycol for encapsulation of islets of Langerhans. (2000) (43)
Molecular mass distribution of sodium alginate by high-performance size-exclusion chromatography. (1999) (43)
An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants (2021) (42)
COVID-19: Staging of a New Disease (2020) (41)
SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol (2005) (38)
Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824) (2017) (35)
Overcoming hypoxia-induced functional suppression of NK cells (2020) (34)
Graphene nanoplatelet and graphene oxide functionalization of face mask materials inhibits infectivity of trapped SARS-CoV-2 (2020) (34)
Learning subgroup-specific regulatory interactions and regulator independence with PARADIGM (2013) (33)
Efficient ADCC- killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. (2019) (33)
Rapid purification of islets using magnetic microspheres coated with anti-acinar cell monoclonal antibodies. (1990) (33)
Prolonged pancreas preservation using a simplified UW solution containing polyethylene glycol. (1991) (31)
Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples (2018) (31)
A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses (2020) (28)
Long-term reversal of diabetes in the large animal model by encapsulated islet transplantation. (1992) (28)
Lymphovascular invasion of colorectal cancer is correlated to SPARC expression in the tumor stromal microenvironment (2011) (26)
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells (2020) (23)
Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice (2021) (22)
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. (2021) (22)
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex (2018) (21)
Glucagon therapy in acute pancreatitis: prospective randomized double-blind study. (1980) (20)
Functioning heterotopic oxyntic mucosa in the rectum. (1980) (20)
Vagal control of gastrin release in the dog: pathways for stimulation and inhibition. (1984) (20)
Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial (2022) (20)
An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma (2019) (19)
Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients. (2021) (19)
Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy (2019) (19)
Toll-like Receptor-4 Activation Boosts the Immunosuppressive Properties of Tumor Cells-derived Exosomes (2019) (18)
Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP Study (2020) (18)
Preliminary phase 2 clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients. (2019) (17)
Fundic inhibition of acid secretion and gastrin release in the dog. (1980) (17)
Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy (2019) (17)
An in vitro method of assessing the immunoprotective properties of microcapsule membranes using pancreatic and tumor cell targets. (1990) (17)
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) (2021) (16)
Use of secretin in the roentgenologic and biochemical diagnosis of duodenal gastrinoma. (1983) (15)
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells (2021) (14)
Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia (2022) (14)
The evaluation of gastric inhibitory polypeptide (GIP) as the enterogastrone. (1979) (14)
601 Increased transport of nanoparticle albumin-bound paclitaxel (ABI-007) by endothelial gp60-mediated caveolar transcytosis: a pathway inhibited by Taxol (2004) (13)
Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge (2021) (13)
Preliminary data from QUILT 3.055: A phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors (CPI). (2021) (12)
Abraxane (ABI-007) vs taxotere: a preclinical comparison of toxicity and efficacy (2005) (12)
Prevention of CTL and NK cell-mediated cytotoxicity by microencapsulation. (1990) (12)
SPARC expression in head and neck cancer correlates with tumor response to nanoparticle albumin-bound paclitaxel (nab-paclitaxel, ABI-007, Abraxane) (2006) (12)
Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice (2021) (11)
Graphene Nanoplatelet and Graphene Oxide Functionalization of Face Mask Materials Inhibits Infectivity of Trapped SARS-CoV-2 (2021) (11)
Glucose‐Insulin Kinetics of the Extravascular Bioartificial Pancreas A Study Using Microencapsulated Rat Islets (1992) (11)
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016 (2017) (11)
Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer (2021) (11)
Encapsulated islet cell therapy for the treatment of diabetes: intraperitoneal injection of islets. (1996) (11)
Intraperitoneal transplantation of microencapsulated canine islet allografts with short-term, low-dose cyclosporine for treatment of pancreatectomy-induced diabetes in dogs. (1994) (10)
Comprehensive genomic transcriptomic tumor-normal gene panel analysis for enhanced precision in patients with lung cancer (2018) (10)
Enhancement of lectin-induced cap formation in human neutrophils by cyclosporin A. (1988) (10)
Specific binding sites for atrial natriuretic factor in the human kidney. (1985) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma (2021) (10)
Utilization of anti-acinar cell monoclonal antibodies in the purification of rat and canine islets. (1990) (10)
Enhanced efficacy and safety of nanoparticle albumin-bound nab-docetaxel versus taxotere. (2006) (9)
Millisecond-scale molecular dynamics simulation of spike RBD structure reveals evolutionary adaption of SARS-CoV-2 to stably bind ACE2 (2020) (9)
Single Prime hAd5 Spike (S) + Nucleocapsid (N) Dual Antigen Vaccination of Healthy Volunteers Induces a Ten-Fold Increase in Mean S- and N- T-Cell Responses Equivalent to T-Cell Responses from Patients Previously Infected with SARS-CoV-2 (2021) (9)
Prime hAd5 Spike + Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants (2021) (9)
Functional maturation of porcine fetal pancreatic explants. (1989) (8)
Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer (2022) (8)
Successful long-term exocrine and endocrine function of the autotransplanted pancreas in humans. (1987) (8)
CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma (2018) (8)
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability (2022) (8)
Experimental Xenotransplantation of Encapsulated Cells (1991) (7)
Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display (2021) (7)
Human C-peptide response in xenotransplanted diabetic Lewis rats. (1992) (7)
NANT cancer vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer. (2019) (6)
Th1 Dominant Nucleocapsid and Spike Antigen-Specific CD4+ and CD8+ Memory T Cell Recall Induced by hAd5 S-Fusion + N-ETSD Infection of Autologous Dendritic Cells from Patients Previously Infected with SARS-CoV-2 (2020) (6)
Breaking Speed and Sensitivity Limits Real-Time Diagnostics with Serial Time-Encoded Amplified Microscopy (2010) (6)
Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient. (2020) (6)
Predicting DNA accessibility in the pan-cancer tumor genome using RNA-seq, WGS, and deep learning (2017) (6)
Bethanechol prevents inhibition of gastric acid secretion by gastric inhibitory polypeptide. (1984) (6)
Novel cytokine–antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma (2020) (6)
Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy (2021) (6)
Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers (2022) (6)
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy. (2021) (5)
Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial (2020) (5)
[A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor]. (2004) (5)
Ultra-low-power semiconductors for wireless vital signs early warning systems (2011) (5)
The Dual-Antigen Ad5 COVID-19 Vaccine Delivered as an Intranasal Plus Subcutaneous Prime Elicits Th1 Dominant T-Cell and Humoral Responses in CD-1 Mice (2021) (5)
Abstract 2302: An ‘off the shelf,’ GMP-grade, IL-2-independent NK cell line expressing the high-affinity Fc-receptor to augment antibody therapeutics (2016) (5)
Intra-Tumor Injection of CAR-Engineered NK Cells Induces Tumor Regression and Protection Against Tumor Re-Challenge (2016) (5)
Cancer moonshot countdown (2016) (4)
539 Comparative pharmacokinetic (PK) study of a cremophor-free, protein stabilized, nanoparticle formulation (ABI-007) and a cremophor-based formulation of paclitaxel (P) in patients with advanced solid tumors (2004) (4)
Islet purification by a novel immunomicrosphere cell depletion technique. (1990) (4)
Positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15RαFc superagonist N-803 (Anktiva) and BCG infusion. (2022) (4)
Deep Learning Implicitly Handles Tissue Specific Phenomena to Predict Tumor DNA Accessibility and Immune Activity (2019) (4)
A tolerability study of a cremophor free, nanoparticle albumin bound paclitaxel intravenously administered in Chinese patients with advanced solid tumor (2005) (4)
Evidence of a noncholecystokinin stimulant of gallbladder contraction: comparison of fasting serum concentrations in healthy subjects and in patients with gallstones. (1985) (4)
Abstract P5-04-02: Safety and efficacy from first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK) in patients with 2nd-line or greater metastatic triple-negative breast cancer (TNBC) (2020) (3)
Immunocytochemical Identification of Monoclonal Antibodies with Binding Activity to Acinar Cells but not Islets (1991) (3)
Metronomic ABI-007 therapy: antiangiogenic and antitumor activity of a nanoparticle albumin-bound paclitaxel (2005) (3)
Anti-angiogenic and antitumor activity of nanoparticle albumin bound (nab) thiocolchicine dimer (IDN5404) with a novel dual mechanism of action on Tubulin and Topoisomerase-1 (2006) (3)
Mechanical obstruction of the portal vein as a cause of vascular thrombosis after pancreatic transplantation in humans. (1988) (3)
A recombinant ‘ACE2 Triple Decoy’ that traps and neutralizes SARS-CoV-2 shows enhanced affinity for highly transmissible SARS-CoV-2 variants (2021) (3)
Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer. (2021) (3)
Cis-Compound Mutations are Prevalent in Triple Negative Breast Cancer and Can Drive Tumor Progression (2016) (3)
Polymeric shells for medical imaging prepared from synthetic polymers, and methods for the use thereof (1996) (3)
Complete responses in patients with second-line or greater metastatic triple negative breast cancer (TNBC) following first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK) (2019) (3)
PLLBA-01 FINAL CLINICAL RESULTS OF PIVOTAL TRIAL OF IL-15RΑFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CIS AND PAPILLARY COHORTS (2022) (3)
Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display (2022) (3)
IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (2022) (3)
Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells (2021) (3)
HER2 and SPARC status in tumors may play an important role in the relative effectiveness of nanoparticle albumin-bound (nab(r)) paclitaxel versus polysorbate-based docetaxel (2008) (3)
Abstract P6-05-08: Integrating whole exome sequencing data with RNAseq and quantitative proteomics to better inform clinical treatment decisions in patients with metastatic triple negative breast cancer (2016) (3)
Pancreas and islet-cell transplantation. Potential cure for diabetes. (1990) (3)
Nab-028, a nanoparticle albumin-bound novel taxane, shows improved efficacy and lower toxicity over the tween formulation (Tween-028) (2005) (3)
Investigating tumoral and temporal heterogeneity through comprehensive -omics profiling in patients with metastatic triple negative breast cancer. (2017) (3)
Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression (2020) (3)
Pancreas function index: an early monitor of allograft rejection. (1991) (3)
505 POSTER Improved effectiveness of nab-paclitaxel versus docetaxel in various xenografts as a function of HER2 and SPARC status (2006) (2)
Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors (2021) (2)
Proceedings of the 2nd Conference on Wireless Health (2011) (2)
A deep learning-based iterative digital pathology annotation tool (2021) (2)
A novel preparation of systemic paclitaxel reduces in-stent restenosis in the rabbit (2002) (2)
Prevention by bethanichol of inhibition of gastric acid secretion by gastric inhibitory polypeptide (GIP) (1980) (2)
Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies (2022) (2)
Tumor Exosomes Mediate the Horizontal Transfer of DNA Gene Mutation (2020) (2)
Early markers of pancreas transplant rejection. (1992) (2)
Absence of the "incretin" phenomenon in the autotransplanted human pancreas. (1988) (2)
Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial. (2018) (2)
Microencapsulated Islets in Type I Diabetics: Clinical Experience (1999) (2)
Identification of novel blood group-reactive monoclonal antibodies cytotoxic to human acinar cells but not islets. (1989) (2)
Non-vasoactive intestinal polypeptide, nonsomatostatin fundic inhibitoy mechanism. (1981) (2)
Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell (1995) (2)
Method for the preparation of fluorocarbon-containing polymeric shells for medical imaging (1996) (2)
SO-28 A randomized phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer (2020) (2)
Pathology image-based lung cancer subtyping using deeplearning features and cell-density maps (2020) (2)
Abstract 393: Predicting DNA accessibility in the pan-cancer tumor genome using RNA-Seq, WGS, and deep learning (2017) (2)
A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells (2022) (2)
Pyloro-oxyntic neurohumoral inhibitory reflex of acid secretion. (1980) (2)
PD09-05 PHASE 2/3 CLINICAL RESULTS OF IL-15RΑFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS) PATIENTS. (2021) (2)
Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T-cell therapy in patients with third line or greater TNBC. (2019) (2)
LBA-18 PRELIMINARY PHASE 2 CLINICAL RESULTS OF IL-15R&agr;FC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS DEMONSTRATES 82% CR OF CARCINOMA IN SITU (CIS) (2019) (1)
Heterologous Vaccination with SARS-CoV-2 Spike saRNA Prime followed by DNA Dual-Antigen Boost Induces Robust Antibody and T-Cell Immunogenicity against both Wild Type and Delta Spike as well as Nucleocapsid Antigens (2021) (1)
Promising survival and disease control in third-line or greater metastatic or locally advanced pancreatic cancer patients following chemo-radiation and novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy. (2022) (1)
Abstract 4512: High-throughput identification of neoepitopes for the development of patient-specific cancer immunotherapies (2016) (1)
Characterization of monoclonal antibodies CBL3 and TT62 with differing antigenic determinants specific for isolated human islets. (1988) (1)
Phase I trial characterizing the pharmacokinetic profile and NK and CD8+ t cell expansion with n-803, a chimeric IL-15 superagonist, in healthy volunteers. (2020) (1)
Providing a Homing Receptor for CAR Engineered NK Cells - Improving Cellular Immunotherapy for B-Cell Lymphoma (2018) (1)
Non-somatostatin, non-VIP fundic inhibition of acid secretion and gastrin release (1980) (1)
Abstract 213: Integrated proteogenomic analysis of laser capture microdissected breast tumors (2017) (1)
Elevation in urinary prostaglandin (PGE2) as an early marker of pancreas allograft rejection. (1989) (1)
Encapsulated Human Islet Transplant Trials in Type I Diabetic Patients (1995) (1)
Abstract 284: Integrated proteogenomic analysis of laser microdissected primary breast tumors define proteome clusters (2018) (1)
Deep Learning with Implicit Handling of Tissue-Specific Phenomena Predicts Tumor DNA Accessibility and Immune Activity (2019) (1)
Immunotherapy combining NK and T cell activation with IL-15 super agonist (N-803), off-the-shelf high-affinity CD16 NK (haNK) or PDL1 targeted haNK and checkpoint inhibitor in relapsed/refractory advanced pancreatic cancer. (2020) (1)
Time-Stretch Imaging and its Applications to High-throughput Microscopy and Microsurgery (2010) (1)
Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer (2022) (1)
Correlation between circulating cell-free RNA biomarkers and response during combination immunotherapy in previously refractory metastatic TNBC patients. (2019) (1)
Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer. (2019) (1)
Macrocapsules cytoprotectrices, biocompatibles et recuperables (1993) (0)
Process for in vivo administration of biological substances and compositions used therefrom (1994) (0)
Abstract 640: Subsets of HLA alleles are capable of binding neoantigens derived from mutations within cancer driving genes such as KRAS and EGFR (2017) (0)
Improved effectiveness of Abraxane versus Taxotere in multiple different xenografts. (2006) (0)
Administration procedure (in vivo) of biologicals and compositions used in these procedures. (1994) (0)
Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer. (2023) (0)
Abstract PO-030: Deep-learning image-based tumor, stroma, and lymphocytes spatial relationships and clinicopathological features that affect survival in pancreatic cancer patients (2020) (0)
Pharmaceutical compositions supply at the site of disease comprising paclitaxel (2005) (0)
Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibroticand/or has a dense stroma (2011) (0)
Genomics, transcriptomics, and proteomics in the clinical setting: Integrating whole genome and RNA sequencing with quantitative proteomics to better inform clinical treatment selection. (2015) (0)
Abstract P6-06-09: Evaluation of laser microdissected primary breast tumors for RNA Seq over bulk processing and validated with cohort control (2020) (0)
Identifying patient-specific neoepitopes for cell-based and vaccine immunotherapy within The Cancer Genome Atlas reveals rarely shared recurrent neoepitopes (2016) (0)
Abstract 2172: Proteogenomics of laser microdissected difficult-to-treat breast cancers identifies Basal and Her2 patients associated with outcome differences (2021) (0)
Networked biocompatible encapsulation compositions and methods (1993) (0)
Protein stabilized pharmaceutical ingredients and the use thereof (1997) (0)
Abstract 479: Modeling miRNA induced silencing in breast cancer with PARADIGM (2017) (0)
NK Cell-Based Immunotherapy Approaches to Sinonasal Undifferentiated Carcinoma (2023) (0)
New formulations of pharmacological agents, methods for their preparation and methods for their use (1998) (0)
Abstract 3171: Deep-learning image-based features stratify risk in HER2- breast cancer patients (2021) (0)
Renal and Pancreas Transplantation in Diabetic Chronic Uremic Patients (1990) (0)
Phase I and Pharmacokinetic Study of ABI-007 , a Cremophor-free , Protein-stabilized , Nanoparticle Formulation of Paclitaxel 1 (2002) (0)
Abstract 3888: The NantOmics Pharmacogenomics Test: An integrative panomic approach to pharmacogenomics screening (2018) (0)
Methods for the in vivo biological compounds and compositions thereof useful for administration. (1994) (0)
Profile: Patrick Soon-Shiong (2011) (0)
Abstract P6-10-04: Landscape of immune-cell signatures in early high-risk breast cancer (BC) reveals clinically-relevant enrichment of immune subpopulations (2020) (0)
The role of tumor-derived exosomes in cancer immune evasion mediated by toll-like receptor 4 activation. (2018) (0)
Background Methods Results Conclusions (2010) (0)
Combination therapy of nanoparticle composition of the taxane and the hedgehog inhibitors (2010) (0)
AVATAR DENDRITIC CELLS: THE NEOANTIGEN NATURAL KILLER T-CELL CHEMO IMMUNO RADIATION COMPOSITION INDUCING IMMUNOGENIC CELL DEATH (2018) (0)
Abstract P1-10-01: Caveolin gene expression predicts for response and clinical outcomes of patients treated with preoperative paclitaxel-based chemotherapy regimens in early stage breast cancer (2020) (0)
Straight talk with...Patrick Soon-Shiong. Interview by Amber Dance. (2012) (0)
formulations of pharmacological agents, methods for their preparation and methods of use thereof (1998) (0)
Abstract P2-04-10: High-affinity activated natural killer (haNK) cells augment trastuzumab efficacy in a mouse model of HER2-positive human metastatic breast cancer (2017) (0)
The Effect of Osteoarthritic Synovial Fluid on Immunomodulatory Properties of Adipose Mesenchymal Stem Cells (2018) (0)
Quilt-3.064: An open-label phase I study of PD-L1 t-haNK in subjects with locally advanced or metastatic solid cancers. (2020) (0)
Inferred immune-cell activity is an independent predictor of HER2 negative breast cancer prognosis and response to paclitaxel-based therapy in the GeparSepto trial. (2023) (0)
Abstract 3402: Evaluation of laser microdissected primary breast tumors for RNA-Seq over bulk processing (2019) (0)
Compositions and methods for administration of pharmacological agents (2003) (0)
Abstract 3372: Differential exon usage in the HER2 subtype of breast cancer identified with RNA-seq and proteomic data (2017) (0)
Urinary insulin as a marker of rejection in the bladder-drained pancreas allograft. (1990) (0)
Pro inflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived exosomes (2018) (0)
OA 18.04 Whole Genome Tumor-Normal Sequencing Reveals Potential False Positives Versus Standard CGP Sequencing in Patients with NSCLC (2017) (0)
Peptidome Surveillance Across Evolving SARS-CoV-2 Lineages Reveals HLA Binding Conservation in Nucleocapsid Among Variants With Most Potential for T-Cell Epitope Loss in Spike (2022) (0)
Wireless Health 2010 (2010) (0)
Toll‐like Receptor‐4 Activation Improves the Immunosuppressive Properties of Cancer Cells‐Derived Exosomes (2018) (0)
A comprehensive analysis of molecular profiles across over 10,000 tumor and germ-line exomes across more than 20 tumor types: Novel mechanisms and targets for clinical treatment. (2014) (0)
The NantOmics Pharmacogenomics Test: An integrative panomic approach to pharmacogenomics screening. (2018) (0)
Abstract 2253: Identifying pathogenic germline variants in 1,172 cancer patients utilizing a novel variant phasing tool and strict public database curation (2018) (0)
Abstract PS11-13: Multidimensional molecular profiling of repeated metastatic TNBC biopsies in the intensive trial of omics safely guides treatment decisions (2021) (0)
Multiomic approach to determine prognosis for patients with HER2-positive breast cancer (2016) (0)
An examination of the use of CD19 CAR NK-92 cells to induce complete remission and vaccine effect against rechallenge in a highly aggressive murine leukemia. (2018) (0)
Abstract A008: AI-driven image-based microbiome analysis reveals correlation of higher pre-treatment microbiome level with complete response in QUILT 3032 trial patients (2022) (0)
Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RαFc superagonist N-803 plus BCG. (2023) (0)
Overall survival in patients with metastatic or locally advanced pancreatic cancer following chemoradiation with novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy. (2023) (0)
PGE2 elevation occurs in the urine in both bladder and duodenally drained pancreas allograft rejection. (1990) (0)
Protein expression by genetic mutations identified in gene panels (hotspots) and efficacy of targeted treatments. (2015) (0)
Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples (2018) (0)
Author Correction: A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability (2022) (0)
Abstract B04: Multimodal cancer immunotherapy combining IL-8 inhibition, adenovirus vaccine, IL-15 super agonist, and anti-PD-L1/TGFβRII agent reduces mesenchymalization and enhances anti-tumor efficacy (2020) (0)
The IL-15 receptor agonist N-803 combined with the anti-CD20 monoclonal antibody rituximab expands NK and CD8 T cells and alters single cell immune transcriptomes in a phase 1 clinical trial in lymphoma (2020) (0)
Abstract 449: Targeted proteomic analysis for personalized treatment of muscle invasive bladder cancer (2016) (0)
General surgery: new advances in pancreatic transplantation. (1987) (0)
Encapsulation procedures and compositions encapsulated biocompatible crosslinked. (1993) (0)
Abstract P1-07-20: Developing prognostic indicators of poor outcomes in PRAEGNANT metastatic breast cancer cohort (2018) (0)
Nanoparticle comprising rapamycin and albumin as an antineoplastic agent (2008) (0)
New formulations of pharmacological agents, to processes for the preparation thereof, and methods of use thereof (1998) (0)
Abstract 25: Whole genome sequencing and quantitative proteomics reveal HPV integration and HER2 overexpression in a patient with cervical cancer: Comprehensive omics analysis driving clinical treatment decisions (2016) (0)
Abstract 4935: Targeted proteomic analysis of hepatocellular carcinoma and its histologic mimickers (2016) (0)
In-situ diversification of immunity following vaccination targeting tumor neoepitopes; an integral component of combinatorial immunotherapy (2019) (0)
Derivatives substituted analogs 18-amino geldanamycin of hydroquinone with cytotoxic activity for the treatment of cancer. (2007) (0)
Methods and compositions for the treatment of recurrent cancer (2008) (0)
Abstract P2-04-26: Identifying patient-specific neoepitopes for cell-based and vaccine immunotherapy across breast cancer classifications reveals rarely shared recurrent neoepitopes (2017) (0)
TCR repertoire analysis from peripheral blood for prognostic assessment of patients during treatment. (2019) (0)
A phase I study of Ad5 PSA/MUC-1/brachyury vaccine in patients with metastatic castration resistant prostate cancer (mCRPC) (2019) (0)
P77.01 Preliminary Data from QUILT 3.055: A Phase 2 Multi-Cohort Study of N803 (IL-15 Superagonist) in Combination with Checkpoint Inhibitors in NSCLC (2021) (0)
Method for the preparation of pharmacologically active agents stabilized with protein (1997) (0)
Focus on personalized molecular based medicine (2012) (0)
Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition (2019) (0)
Tumor-normal sequencing to reveal frequency of false positive error rates with tumor-only sequencing in GI cancers and with RNA sequencing as a new standard of precision molecular profiling. (2018) (0)
Preparation and evaluation of novel derivatives of geldanamycin (2006) (0)
A method for the in vivo administration of biological substances usable for this purpose and compositions (1994) (0)
Toll-like Receptor-4 Activation Boosts the Immunosuppressive Properties of Tumor Cells-derived Exosomes (2019) (0)
Abstract P2-11-12: Novel protocol combining metronomic nant-paclitaxel with HER2-targeted natural killer cells (innate immunotherapy) for HER2-positive metastatic breast cancer (2016) (0)
A process for the (in vivo) the delivery of biological materials and compositions which are useful therefor (1994) (0)
Identifying patient-specific neoepitopes for cell-based and vaccine immunotherapy targets in breast cancer patients by HLA typing and predicting MHC presentation from whole genome and RNA sequencing data. (2016) (0)
pharmacologically active agents coated with protein and their use (1997) (0)
Enabling content through interactions based authentication systems and method (2013) (0)
21P BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC) (2021) (0)
Abstract PR20: A novel combination immunotherapy with a vaccine targeting tumor neoepitopes that mediates immune cascade in murine tumor models (2020) (0)
A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival (2020) (0)
Abstract P6-04-14: Integrating whole genome sequencing data with RNAseq, pathway analysis, and quantitative proteomics to determine prognosis after standard adjuvant treatment with trastuzumab and chemotherapy in primary breast cancer patients (2016) (0)

This paper list is powered by the following services:

Other Resources About Patrick Soon-Shiong

en.wikipedia.org

What Schools Are Affiliated With Patrick Soon-Shiong?

Patrick Soon-Shiong is affiliated with the following schools:

Patrick Soon-Shiong's Academic­Influence.com Rankings